Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
Diego Kauffmann-Guerrero, Rudolf Maria Huber Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich, University of Munich (LMU), Comprehensive Pneumology Center, Member of the German Center for Lung Research (DZL), Munich, German...
Guardado en:
Autores principales: | Kauffmann-Guerrero D, Huber RM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ec7e22730186457e9bbe75d631e22ff1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A review and update on orphan drugs for the treatment of noninfectious uveitis
por: You C, et al.
Publicado: (2017) -
Small cell lung cancer transformation during antitumor therapies: A systematic review
por: Chai Xing, et al.
Publicado: (2021) -
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
por: Man He, et al.
Publicado: (2021) -
Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
por: Vicky Mai, et al.
Publicado: (2021) -
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells
por: Tian H, et al.
Publicado: (2016)